Q2 EPS Estimates for OPKO Health Lowered by Zacks Research

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Equities research analysts at Zacks Research lowered their Q2 2025 earnings estimates for shares of OPKO Health in a report released on Wednesday, May 21st. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earnings of ($0.09) per share for the quarter, down from their prior estimate of ($0.07). The consensus estimate for OPKO Health's current full-year earnings is ($0.25) per share. Zacks Research also issued estimates for OPKO Health's Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.37) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.11) EPS.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.03). OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm had revenue of $149.90 million during the quarter, compared to the consensus estimate of $163.13 million. During the same quarter in the previous year, the firm earned ($0.12) EPS. The business's revenue for the quarter was down 13.7% on a year-over-year basis.

Other equities research analysts have also issued reports about the stock. Barrington Research reissued an "outperform" rating and issued a $2.25 target price on shares of OPKO Health in a report on Thursday, May 1st. Wall Street Zen downgraded OPKO Health from a "hold" rating to a "sell" rating in a report on Monday, May 5th. HC Wainwright restated a "buy" rating and issued a $3.00 price objective on shares of OPKO Health in a report on Monday, April 7th. Finally, JPMorgan Chase & Co. began coverage on OPKO Health in a report on Friday, April 25th. They issued a "neutral" rating for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $2.75.

OPKO Health Stock Performance

NASDAQ:OPK traded up $0.05 during mid-day trading on Monday, reaching $1.31. The company's stock had a trading volume of 2,396,242 shares, compared to its average volume of 3,908,235. OPKO Health has a 12-month low of $1.19 and a 12-month high of $2.04. The firm's fifty day moving average price is $1.44 and its two-hundred day moving average price is $1.55. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The stock has a market cap of $1.04 billion, a P/E ratio of -6.89 and a beta of 1.42.

Insider Activity at OPKO Health

In related news, CEO Phillip Md Et Al Frost bought 200,000 shares of the company's stock in a transaction on Monday, March 17th. The stock was bought at an average cost of $1.74 per share, for a total transaction of $348,000.00. Following the acquisition, the chief executive officer now directly owns 213,501,448 shares in the company, valued at $371,492,519.52. This represents a 0.09% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last ninety days, insiders bought 767,434 shares of company stock valued at $1,238,312. 49.69% of the stock is owned by insiders.

Hedge Funds Weigh In On OPKO Health

A number of hedge funds have recently modified their holdings of OPK. Caxton Associates LLP purchased a new position in OPKO Health during the 1st quarter valued at about $130,000. Voleon Capital Management LP acquired a new position in shares of OPKO Health in the first quarter valued at approximately $45,000. Goldman Sachs Group Inc. increased its holdings in shares of OPKO Health by 4.2% in the first quarter. Goldman Sachs Group Inc. now owns 4,001,214 shares of the biotechnology company's stock valued at $6,642,000 after purchasing an additional 161,394 shares during the period. Millennium Management LLC grew its holdings in OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company's stock worth $10,602,000 after acquiring an additional 1,798,385 shares during the period. Finally, AQR Capital Management LLC grew its holdings in OPKO Health by 466.7% during the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company's stock worth $2,671,000 after acquiring an additional 1,324,988 shares during the period. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.